Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Adjunctive D-cycloserine with iTBS in MDD
NCT05731323Phase 1Completed
- Sponsor
- University of Calgary
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of d-cycloserine in major depressive disorder (MDD), sponsored by University of Calgary. Primary endpoints: Montgomery-Asberg Depression Rating Scale at Week 8, Individual differences in D-cycloserine serum concentration correlation with clinical outcomes at Day 6 and 3 more. Started Oct 2022; status: completed.
02
Drugs
d-cycloserine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05731323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731323.